Authors
Latest:
The Burgeoning Specialty Drug Market: A Case for Guaranteed ValueAn actionable perspective on the future of specialty drug value-based contracting
Latest:
Plan of attack for small company supplier negotiationsHow emerging life sciences organizations can create value with suppliers
Latest:
Bridging the Divide: Understanding Contrasting Approaches in Drug DevelopmentAnalyzing the divergent paths undertaken by small biotech and large pharma companies in drug development.
Latest:
Preparing for Peak Season with Temperature-controlled ContainersThe pharma logistics peak season—and most of 2022—is going to be challenging for pharmaceutical shippers, forwarders and the air cargo industry. But making slight changes—such as choosing the right packaging—can make it easier.
Latest:
Navigating the Complexities of Prescription Drug Pricing: Affordable Solutions Are Available to Self-Insured Plan SponsorsThe lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.
Latest:
The CGT Evolution: Key ConsiderationsHow cell and gene therapies can be safely protected as they move along the supply chain, even when temperature-related challenges present themselves.
Latest:
High-Tech Hubs and Specialty PharmaWith the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.
Latest:
In the Shadows of the Drug Affordability Debate, Patients Pay the Ultimate PriceAll healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.
Latest:
Strengthening the Cold Chain: Insights Gained from COVID-19A breakdown of how the industry is using these lessons to move full steam ahead.
Latest:
CSA a Game Changer for the Life Sciences?Exploring the FDA’s latest proposed guidance on computer system validation, and the movement toward a less burdensome approach
Latest:
An Economic Path Forward: Thoughts on an Industry Inflection PointThe life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.
Latest:
Strategies to Modernize, Future-Proof, and Secure the Healthcare Supply ChainEnsuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.
Latest:
An Economic Path Forward: Thoughts on an Industry Inflection PointThe life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.
Latest:
Tapping into Digital IntelligenceUsing technology to personalize customer engagement, build HCP trust.
Latest:
The Do’s of Evaluating Cell Sourcing PartnersFactors to keep in mind before obtaining material in the cell therapy space.
Latest:
Benefits of Structured Content in Preparing Data for Regulatory SubmissionsHow taking steps to incorporate data into all regulatory and labeling operations helps firms avoid retroactively planning to recapture information
Latest:
How Do Drug Shortages Affect Pharmacovigilance?Drug shortages, including critical antibiotics, fever medications, and cancer treatments, highlight global supply chain issues and the need for improved health policies to prevent medication bottlenecks.
Latest:
The Evolving Value Assessment Landscape in the USHow current frameworks influence coverage decisions and pricing negotiations.
Latest:
Bridging the Gap Between Strategy and Practice in IDN PartnershipsIn order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).
Latest:
Understanding the FDA's Exemption for DSCSA ComplianceIn the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Latest:
DSCSA 2024 or 2023 Déjà Vu?A look at the challenges that need to be addressed during the FDA stabilization period.
Latest:
Challenges in Cell and Gene Therapy Manufacturing, Sterility AssuranceManufacturers should leverage the knowledge base of personnel working in sterility assurance and in microbiology laboratories.
